GlassScriptPhysician profile
Tuow Daniel Ting
NPI 1043244437
$1,184.37
in general payments reported to CMS, 2019-2025
11 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $80.55 · 2021: $20.52 · 2022: $110 · 2023: $206 · 2024: $221 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $570.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $305.82 | 2019-2025 | Vabysmo |
| Alimera Sciences, INC. | $272.91 | 2019-2022 | |
| Astellas Pharma US INC | $136.31 | 2023-2025 | Izervay |
| Kala Pharmaceuticals, INC. | $124.85 | 2019 | |
| Abbvie INC. | $96.84 | 2023-2025 | Ozurdex |
| Novartis Pharmaceuticals Corporation | $69.21 | 2019 | |
| Ocular Therapeutix, INC. | $65.21 | 2024 | Dextenza |
| Biogen, INC. | $47.08 | 2022 | |
| Apellis Pharmaceuticals, INC. | $24.87 | 2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $20.75 | 2023 | Eylea |
| Optos, INC. | $20.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tuow Ting listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.